Table 1.
Characteristics of t(8;21) AML patients
| Case no. | Age/ sex | FAB | Therapy | Remission duration at sampling, Mo | Total remission duration, Mo | AML1/ETO+ colonies, % |
|---|---|---|---|---|---|---|
| 1 | 31/M | M2 | — | at Dx | — | ND |
| 2 | 48/M | M2 | — | at Dx | — | 59.7 |
| 3 | 46/F | M2 | — | at Dx | — | 75.0 |
| 4 | 45/M | M2 | — | at Dx | — | 57.1 |
| 5a | 49/M | M2 | — | at Dx | — | 66.7 |
| 5b | Auto-MBT | 13 | +18 | 2.8 | ||
| 6a | 20/M | M2 | — | at Dx | — | 61.9 |
| 6b | Auto-MBT | 13 | +18 | 2.1 | ||
| 7a | 47/M | M2 | Auto-MBT | 15 | +99 | 2.6 |
| 7b | 27 | +87 | 0.8 | |||
| 8a | 33/F | M2 | Auto-MBT | 49 | +131 | 2.5 |
| 8b | 60 | +120 | 0 | |||
| 9 | 31/M | M2 | Auto-MBT | 37 | +97 | 2.2 |
| 10 | 21/F | M2 | Auto-MBT | 39 | +99 | 1.6 |
| 11 | 37/F | M2 | Ch-Tx | 12 | +72 | 2.9 |
| 12 | 32/M | M2 | Ch-Tx | 18 | +78 | 3.1 |
| 13 | 62/M | M2 | Ch-Tx | 18 | +78 | 3.4 |
| 14 | 57/M | M2 | Ch-Tx | 28 | +88 | 4.7 |
| 15 | 28/F | M2 | Ch-Tx | 30 | +90 | 2.5 |
| 16 | 45/M | M2 | Ch-Tx | 34 | +94 | 2.7 |
| 17 | 41/F | M1 | Ch-Tx | 34 | +94 | 3.0 |
| 18 | 52/F | M2 | Ch-Tx | 37 | +97 | 1.9 |
| 19 | 35/F | M2 | Ch-Tx | 45 | +105 | 2.0 |
| 20 | 19/M | M1 | Ch-Tx | 49 | +109 | 1.6 |
| 21 | 53/F | M2 | Ch-Tx | 50 | +110 | 1.6 |
| 22 | 20/M | M2 | Ch-Tx | 80 | +140 | 1.7 |
| 23 | 52/M | M2 | Ch-Tx | 88 | +148 | 0.8 |
| 24 | 31/M | M2 | Ch-Tx | 124 | +184 | 0.7 |
| 25 | 54/M | M2 | Ch-Tx | 150 | +210 | 0.8 |
FAB: Classification of AML according to the French-American-British classification; auto-MBT: autologous MBT; Ch-Tx: chemotherapy; at Dx: samples of blastic BM cells were collected at diagnosis; Mo: months; ND: not done. Total percentages of AML1/ETO+ colonies included CFU-GM, BFU-E, CFU-Meg, and CFU-Mix. Detailed data are shown in Table 4 and in our previous report (10).